How much prophylaxis is enough in haemophilia?

Abstract

AbstractIntroductionProphylaxis has become standard of care for all persons with haemophilia (PWH) with a severe phenotype. However, ‘standard prophylaxis’ with either factor or non‐factor therapies (currently only emicizumab available) is prohibitively expensive for much of the world. We sought to address the question of ‘How much prophylaxis is enough?’ and ‘Can it be individualized?’ and specifically ‘Can emicizumab be individualized?’.MethodsWe reviewed the literature on prophylaxis in haemophilia since its inception in the 1950s to the present, the development of more and less intense factor prophylaxis regimens and their outcomes and additionally the published outcomes of prophylaxis with low dose emicizumab.ResultsWhat these experiences collectively show is that low dose emicizumab does result in significant benefits to patients whilst being much less expensive than a “one size fits all” emicizumab prophylaxis approach. We also took note that some non‐factor therapies still in development are individualized given that high doses of these can potentially put patients at risk.ConclusionsProphylaxis is now clearly accepted as standard of care for PWH with a severe phenotype but now in a very short time a large assortment of different treatment options for prophylaxis have become/are becoming available and the haemophilia community will need to determine how to best use these recognizing that no ‘one treatment fits all’.